U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C43H48N2O6S2
Molecular Weight 752.981
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 4
Charge 0

SHOW SMILES / InChI
Structure of INDOCYANINE GREEN ACID FORM

SMILES

CC1(C)C(=CC=CC=CC=CC2=[N+](CCCCS([O-])(=O)=O)C3=CC=C4C=CC=CC4=C3C2(C)C)N(CCCCS(O)(=O)=O)C5=CC=C6C=CC=CC6=C15

InChI

InChIKey=BDBMLMBYCXNVMC-UHFFFAOYSA-N
InChI=1S/C43H48N2O6S2/c1-42(2)38(44(28-14-16-30-52(46,47)48)36-26-24-32-18-10-12-20-34(32)40(36)42)22-8-6-5-7-9-23-39-43(3,4)41-35-21-13-11-19-33(35)25-27-37(41)45(39)29-15-17-31-53(49,50)51/h5-13,18-27H,14-17,28-31H2,1-4H3,(H-,46,47,48,49,50,51)

HIDE SMILES / InChI

Molecular Formula C43H48N2O6S2
Molecular Weight 752.981
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 4
Optical Activity NONE

ICG is a cyanine fluorescent dye which is used in medicine as an indicator substance (for photometric hepatic function diagnostics and fluorescence angiography) in cardiac, circulatory, hepatic and ophthalmic conditions. It is administered intravenously and, depending on liver performance, is eliminated from the body with a half life of approx. 3-4 minutes.

CNS Activity

Curator's Comment: Known to be CNS non-penetrant in mice and rabbits, where it was used to monitor BBB disruptions. Human data not available.

Approval Year

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Diagnostic
IC-GREEN INJECTABLE

Approved Use

Indocyanine Green is indicated for determining cardiac and heptic output during various types of surgeries.

Launch Date

1959
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
68095.1 ng/mL
15 mg/kg single, intravenous
dose: 15 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
INDOCYANINE GREEN ACID FORM plasma
Rattus norvegicus
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
121.6 μg × min/mL
0.5 mg/kg single, intravenous
dose: 0.5 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered: TRIAZOLAM
INDOCYANINE GREEN ACID FORM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
85 mg × min/L
0.5 mg/kg single, intravenous
dose: 0.5 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
INDOCYANINE GREEN ACID FORM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
503070.1 ng × min/mL
15 mg/kg single, intravenous
dose: 15 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
INDOCYANINE GREEN ACID FORM plasma
Rattus norvegicus
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
2.06 min
0.5 mg/kg single, intravenous
dose: 0.5 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered: TRIAZOLAM
INDOCYANINE GREEN ACID FORM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
3.9 h
0.5 mg/kg single, intravenous
dose: 0.5 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
INDOCYANINE GREEN ACID FORM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
79.5 min
15 mg/kg single, intravenous
dose: 15 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
INDOCYANINE GREEN ACID FORM plasma
Rattus norvegicus
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
5%
INDOCYANINE GREEN ACID FORM serum
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
5 mg single, intravenous
Dose: 5 mg
Route: intravenous
Route: single
Dose: 5 mg
Sources:
unhealthy, 46
n = 1
Health Status: unhealthy
Age Group: 46
Sex: M
Population Size: 1
Sources:
Other AEs: Anaphylactoid reaction...
Other AEs:
Anaphylactoid reaction
Sources:
27 mg single, intravenous
Dose: 27 mg
Route: intravenous
Route: single
Dose: 27 mg
Sources:
unhealthy, 48
n = 1
Health Status: unhealthy
Age Group: 48
Sex: M
Population Size: 1
Sources:
Other AEs: Anaphylactoid reaction...
Other AEs:
Anaphylactoid reaction
Sources:
5 mg single, intravenous
Dose: 5 mg
Route: intravenous
Route: single
Dose: 5 mg
Sources:
unhealthy, 63
n = 1
Health Status: unhealthy
Condition: heart failure
Age Group: 63
Sex: M
Population Size: 1
Sources:
Other AEs: Anaphylactoid reaction...
Other AEs:
Anaphylactoid reaction
Sources:
5 mg single, intravenous
Dose: 5 mg
Route: intravenous
Route: single
Dose: 5 mg
Sources:
unhealthy, 66
n = 1
Health Status: unhealthy
Age Group: 66
Sex: M
Population Size: 1
Sources:
Other AEs: Anaphylactoid reaction...
Other AEs:
Anaphylactoid reaction
Sources:
0.5 mg/kg single, intravenous
Dose: 0.5 mg/kg
Route: intravenous
Route: single
Dose: 0.5 mg/kg
Sources:
unhealthy, 70
n = 1
Health Status: unhealthy
Age Group: 70
Sex: F
Population Size: 1
Sources:
Other AEs: Anaphylactoid reaction...
Other AEs:
Anaphylactoid reaction
Sources:
AEs

AEs

AESignificanceDosePopulation
Anaphylactoid reaction
5 mg single, intravenous
Dose: 5 mg
Route: intravenous
Route: single
Dose: 5 mg
Sources:
unhealthy, 46
n = 1
Health Status: unhealthy
Age Group: 46
Sex: M
Population Size: 1
Sources:
Anaphylactoid reaction
27 mg single, intravenous
Dose: 27 mg
Route: intravenous
Route: single
Dose: 27 mg
Sources:
unhealthy, 48
n = 1
Health Status: unhealthy
Age Group: 48
Sex: M
Population Size: 1
Sources:
Anaphylactoid reaction
5 mg single, intravenous
Dose: 5 mg
Route: intravenous
Route: single
Dose: 5 mg
Sources:
unhealthy, 63
n = 1
Health Status: unhealthy
Condition: heart failure
Age Group: 63
Sex: M
Population Size: 1
Sources:
Anaphylactoid reaction
5 mg single, intravenous
Dose: 5 mg
Route: intravenous
Route: single
Dose: 5 mg
Sources:
unhealthy, 66
n = 1
Health Status: unhealthy
Age Group: 66
Sex: M
Population Size: 1
Sources:
Anaphylactoid reaction
0.5 mg/kg single, intravenous
Dose: 0.5 mg/kg
Route: intravenous
Route: single
Dose: 0.5 mg/kg
Sources:
unhealthy, 70
n = 1
Health Status: unhealthy
Age Group: 70
Sex: F
Population Size: 1
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
Drug as perpetrator​Drug as victim
PubMed

PubMed

TitleDatePubMed
Survey of complications of indocyanine green angiography in Japan.
1994 Dec 15
Hypotensive shock as a complication of infracyanine green injection.
1998
Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11).
2013 Dec
Patents

Sample Use Guides

The usual doses of Indocyanine Green for Injection USP for dilution curves are as follows: adults - 5.0 mg, children - 2.5 mg, infants - 1.25 mg. These doses of the dye are usually injected in 1 mL volume. An average of five dilution curves are recommended in the performance of a diagnostic cardiac catheterization. The total dose of dye injected should be kept below 2 mg/kg.
Route of Administration: Intravenous
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Sat Dec 16 01:38:29 GMT 2023
Edited
by admin
on Sat Dec 16 01:38:29 GMT 2023
Record UNII
C4V974V932
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
INDOCYANINE GREEN ACID FORM
Common Name English
NK-5078
Code English
CRYSTA-LYN 551522
Brand Name English
1H-BENZ(E)INDOLIUM, 2-(7-(1,3-DIHYDRO-1,1-DIMETHYL-3-(4-SULFOBUTYL)-2H-BENZ(E)INDOL-2-YLIDENE)-1,3,5-HEPTATRIEN-1-YL)-1,1-DIMETHYL-3-(4-SULFOBUTYL)-, INNER SALT
Common Name English
NK 5078
Code English
Code System Code Type Description
EPA CompTox
DTXSID9048279
Created by admin on Sat Dec 16 01:38:29 GMT 2023 , Edited by admin on Sat Dec 16 01:38:29 GMT 2023
PRIMARY
PUBCHEM
71587099
Created by admin on Sat Dec 16 01:38:29 GMT 2023 , Edited by admin on Sat Dec 16 01:38:29 GMT 2023
PRIMARY
FDA UNII
C4V974V932
Created by admin on Sat Dec 16 01:38:29 GMT 2023 , Edited by admin on Sat Dec 16 01:38:29 GMT 2023
PRIMARY
DRUG BANK
DB09374
Created by admin on Sat Dec 16 01:38:29 GMT 2023 , Edited by admin on Sat Dec 16 01:38:29 GMT 2023
PRIMARY
RXCUI
2199577
Created by admin on Sat Dec 16 01:38:29 GMT 2023 , Edited by admin on Sat Dec 16 01:38:29 GMT 2023
PRIMARY
CAS
28782-33-4
Created by admin on Sat Dec 16 01:38:29 GMT 2023 , Edited by admin on Sat Dec 16 01:38:29 GMT 2023
PRIMARY
DAILYMED
C4V974V932
Created by admin on Sat Dec 16 01:38:29 GMT 2023 , Edited by admin on Sat Dec 16 01:38:29 GMT 2023
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
Related Record Type Details
ACTIVE MOIETY